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Abstract NT-proBNP, a marker of cardiac failure, has been
shown to be stable in post mortem samples. The aim of this
study was to assess the accuracy of NT-proBNP to detect
heart failure in the forensic setting. One hundred sixty-eight
consecutive autopsies were included in the study. NT-
proBNP blood concentrations were measured using a
chemiluminescent immunoassay kit. Cardiac failure was
assessed by three independent forensic experts using
macro- and microscopic findings complemented by infor-
mation about the circumstances of body discovery and the
known medical story. Area under the receiving operator
curve was of 65.4% (CI 95%, from 57.1 to 73.7). Using a
standard cut-off value of >220 pg/mL for NT-proBNP
blood concentration, heart failure was detected with a
sensitivity of 50.7% and a specificity of 72.6%. NT-
proBNP vitreous humor values were well correlated to the
ones measured in blood (r2=0.658). Our results showed
that NT-proBNP can corroborate the pathological findings
in cases of natural death related to heart failure, thus,
keeping its diagnostic properties passing from the ante
mortem to the post mortem setting. Therefore, biologically
inactive polypeptides like NT-proBNP seem to be stable
enough to be used in forensic medicine as markers of
cardiac failure, taking into account the sensitivity and
specificity of the test.
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Introduction
NT-proBNP is the amino-terminal fragment of the prohor-
mone of BNP (brain natriuretic peptide), which is secreted
mainly by atrial or ventricular myocardial cells, essentially
in response to ventricular wall stress. The biological actions
of BNP include diuresis, vasodilatation, reduction of
systemic and regional (renal and cardiac) sympathetic tone,
myocardial relaxation, anti-hypertrophic and anti-fibrotic
effects and cytoprotection of cardiomyocytes [1].
In clinical practice, BNP and NT-proBNP have been
introduced because of their stability in biological specimens
and their utility in the management of suspected or
established heart failure (diagnosis, prognosis and guided
medical treatment) [2–7].
Natriuretic cardiac peptides have also recently been
evaluated as biomarkers of cardiac function in medicolegal
practice. In the few previous studies on post mortem
measurements of these peptides, attention was paid to
BNP and ANP (atrial natriuretic peptide) [8]. NT-proBNP
seems to be a more reliable biomarker than BNP and ANP
because of its greater stability and longer half-life [6, 9–11].
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This was confirmed in one post mortem study, where NT-
proBNP has been shown to be stable over 24 days in blood
and pericardial fluid sampled from bodies with a post
mortem interval up to 24 h. In particular, after 24 days of
storage at −20°C, NT-proBNP concentration in pericardial
fluid decreased by no more than 16% [12]. NT-proBNP
could therefore be useful in cases where routine autopsy
evaluation is limited (putrefaction, severe trauma, etc.).
However, the ability of this biomarker to identify cardiac
failure at post mortem examination remains unknown.
Therefore, the goal of this study was to estimate the
diagnostic accuracy of NT-proBNP in assessing cardiac
failure compared to standard post mortem investigations
performed in bodies with a post mortem interval compara-
ble to the one selected for the stability study [12], i.e. up to
24 h.
Materials and methods
Objectives
Our main objective was to measure sensitivity, specificity,
positive and negative predictive values, likelihood ratios of
NT-proBNP blood concentration to suspect cardiac failure
at post mortem examination. Our secondary objective was
to measure correlations between NT-proBNP blood con-
centrations and those measured in other available fluids
(serum, pericardial fluid, vitreous humor). Moreover, we
aimed to quantify the eventual influence of age, sex, BMI,
other diseases known to modify the NT-proBNP levels and
traumatic death on the sensitivity and specificity of NT-
proBNP blood levels in detecting heart failure.
Studied population
One hundred sixty-eight out of 210 consecutive medico-
legal autopsies performed at the University Centre of
Legal Medicine of Lausanne in 2006 were included in
this study. To be included, standard investigation proce-
dures (autopsy, histology, toxicology) had to be made
and subjects had to be older than 15 years. The post
mortem interval ranged from <12 to 24 h. Bodies with a
post mortem interval >24 h were excluded from the
study because putrefaction, at any stage, would have
rendered impossible or at least very difficult to identify
signs of heart failure at autopsy and thus to compare
them with the NT-proBNP values measured in various
body fluids most of which, moreover, would have been
unavailable in case of putrefaction. All autopsies were
demanded by legal authorities. The sample reflected the
variability of cases seen in forensic post mortem
evaluations, as it is illustrated in Table 1.
Reference test
No gold standard is available in forensic setting. The
reference test is the usual procedure used when all available
investigations can be performed in usual forensic practice.
The diagnosis of heart failure was based on autopsy
findings including cardiac cavities dilatation with or
without myocardial hypertrophy, visceral congestion of
internal organs, lung and/or peripheral oedema. Moreover,
the presence of referred or detected pre-existing pathologies
known to be causally associated with this syndrome (as
coronary artery disease, hypertension, obesity and valvular
heart disease) was considered in corroborating the diagnosis
of heart failure.
For each case, a complete autopsy was performed,
followed by routine histological examination. Details for
each case were extracted from the autopsy report and
completed by complementary information (sequence of
events, circumstances of body discovery, known medical
story).
All autopsies were performed by seven physicians,
following international recommendations [13]. Three of
these physicians were senior residents with at least 10 years
of experience in forensic medicine, and 4 of them were
residents, always supervised by a senior. All these forensic
pathologists were blinded to NT-proBNP lab results.
Two independent forensic pathologists assessed their
appreciation of cardiac failure for each case using a four-
item Likert scale (most unlikely, unlikely, very likely,
certainly). For cases where experts disagreed, a third
forensic pathologist gave his opinion and cases were
discussed until a consensus was reached. In their evalua-
tions, these examiners were blinded to NT-proBNP values.
Subjects were considered as having suffered from cardiac
failure if assessors agreed they were very likely or certainly
affected by this condition.
Index test (NT-proBNP)
Index test was performed after the reference test (prospec-
tive). Femoral blood, serum, vitreous humor and pericardial
fluid were collected during the autopsy. Serum was
obtained by centrifugation of blood samples, immediately
after collection. Samples were sent by the forensic
examiner to the laboratory and the specimens were stored
at −20°C until the time of analysis. Laboratory staff, who
reported results, was completely blinded to information
regarding cases, except for gender and age. NT-proBNP
blood concentrations were measured using a chemilumi-
nescent immunoassay kit (Elecsys 2010 analyser, Roche
Diagnostic, Basel, Switzerland; Dimension Xpand plus,
Dade Behring, Deerfield, IL, USA). The procedure’s test
performances were the following: CV inter-assay 9% (490±
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44 pmol/L), CV intra-assay 7.3% (431±32 pmol/L) and
9.7% (1,400±135 pmol/L). No cross-reactivity for human
BNP, ANP or N-terminal proANP. LOD 9.7 pmol/l [7]. As
serum is not always available in forensic setting (haemol-
ysis), we chose blood as a reference standard, and we
defined the clinical serum value of >112 pg/mL as cut-off
also for NT-proBNP blood concentration. To test whether
NT-proBNP blood values are correlated to those measured
in serum, pericardial fluid and vitreous humor, the same
laboratory method was applied to these fluids.
Characteristics Cardiac failure
With n=73 Without n=95 p value
Age/gender (n,%) <0.001
Male <55 years 28 (38.4%) 54 (56.8%)
Male ≥55 years 26 (35.6%) 5 (5.3%)
Female <65 years 11 (15.1%) 30 (31.6%)
Female ≥65 years 8 (11.0%) 6 (6.3%)
BMI (kg/m2) 26.5 (5.4) 25.2 (5.7) 0.147
Cause of death (n,%) <0.001
Natural
Cardiovascular system 31 (42.5%) 0 (0%)
Other 10 (13.7%) 13 (13.7%)
Violent death
Trauma 13 (17.8%) 33 (34.7%)
Other violent deaths 14 (19.2%) 45 (47.4%)
Unknown 5 (6.8%) 4 (4.2%)
Autopsy findings
Heart weight; mean (SD), g 448 (104) 348 (80) <0.001
Ventricles
Right dilatation (n,%) 26 (35.6%) 18 (18.9%) 0.015
Right hypertrophy (n,%) 29 (39.7%) 3 (3.2%) <0.001
Left dilatation (n,%) 29 (39.7%) 14 (14.7%) <0.001
Left hypertrophy (n,%) 36 (49.3%) 2 (2.1%) <0.001
Coronary arteries
Stenosis >75% (n,%) 18 (24.7%) 1 (1.0%) <0.001
Thrombosis (n,%) 11 (15.1%) 0 (0%) <0.001
Haemorrhage (n,%) 9 (12.3%) 0 (0%) <0.001
Macroscopy of heart
Fibrosis (n,%) 3 (4.1%) 1 (1.0%) 0.198
Signs of infarction (n,%) 12 (16.4%) 5 (5.3%) 0.017
Valvular insufficiency (n,%) 2 (2.7%) 0 (0%) 0.105
Histological findings
Acute ischemia/infarction (n,%) 36 (49.3%) 23 (24.2%) 0.001
Fibrosis/hypertrophy (n,%) 62 (84.9%) 45 (47.4%) <0.001
Coronary wall thickness >30% (n,%) 35 (47.9%) 16 (16.8%) <0.001
Other disease known to increase NT-proBNP 50 (68.5%) 38 (40%) <0.001
Degenerative or vascular path CNS (n,%) 8 (11.0%) 5 (5.3%) 0.171
Pulmonary hypertension (n,%) 17 (23.3%) 8 (8.4%) 0.007
Pulmonary thromboembolism (n,%) 3 (4.1%) 1 (1.0%) 0.198
Chronic bronchitis (n,%) 15 (20.5%) 4 (4.2%) 0.001
Renal vascular pathology (n,%) 26 (35.6%) 15 (15.8%) 0.003
Liver steatofibrosis (n,%) 5 (6.8%) 8 (8.4%) 0.705
Severe arteriosclerosis (n,%) 41 (56.2) 24 (25.3%) <0.001
Blood alcohol positivitiesa (n,%) 17 (23.3%) 30 (31.6%) 0.235
Table 1 Characteristics of
subjects (n=168)
a Samples with >0.1 g/kg blood
alcohol concentration measured
by Head-Space-GC-FID, were
considered as positive
SD standard deviation
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Other measures
Myocardial specimens for the histological examination
were derived from at least five different topographic
locations, namely left anterior, left lateral, left posterior,
septal and right lateral. They were stained with hematox-
ylin–eosin. For each case, alcohol concentration was
assessed in peripheral blood. Toxicological analyses were
performed, when requested, by GC/MS. The presence of
common abuse substances was assessed, including cocaine
and its metabolites, and the results were compared to
published data [14].
Statistical analyses
Receiver operating curve and area under the curve (AUC)
were calculated for different NT-proBNP values. In the
clinical setting, the reference ranges for NT-proBNP vary
depending on the assay method used and the nature of the
control population [15, 16]. A suggested “normal” range for
NT-proBNP is 68–112 pg/mL [5, 16]. Thus, we chose a
cut-off value of >112 pg/mL to define NT-proBNP as
positive or negative. Sensitivity, specificity, positive and
negative predictive values, positive and negative likelihood
ratios were then given with 95% confidence intervals (95%
CI). Sensitivity and specificity were calculated for sub-
populations (age and sex, BMI, presence of renal, pulmo-
nary and central nervous system pathology, signs of
trauma). Linear regression analysis was used to define
association between NT-proBNP concentrations in blood
and in other biological fluids. Transformations were used to
test other associations than linear correlations, when
required. R2 from the regression was calculated to estimate
the strength of the association between blood and other
body fluids. Analyses were conducted using STATA 10.1
(College Station, TX 77845 USA).
Results
From 210 consecutive autopsies performed from January to
December 2006, 168 were included in the analysis. Criteria
for exclusions are given in Fig. 1.
The two initial assessors agreed on the presence of
cardiac failure from the results given in the autopsy
report for 135 cases (80.4%) showing a substantial
agreement (kappa=0.61) using Landis and Koch’s inter-
pretation of kappa values [17]. Total agreement among
the three experts was easily reached for the remaining 33
cases (19.6%). Cardiac failure was considered as certain
for 27 cases (15.9%), very likely for 46 cases (27.4%),
unlikely for 46 cases (27.4%) and most unlikely for 49
cases (29.2%).
Characteristics of cases with or without heart failure and
levels of significance (p values) are reported in Table 1.
Subjects with heart failure were older than those without
this condition and they were more often of male gender.
Among them, death was more recurrently natural, related to
cardiovascular diseases. Furthermore, subjects with heart
failure were more likely to present other diseases known to
influence NT-proBNP values (p<0.001). Finally, victims
who died from traumatic causes were two times less likely
to suffer from heart failure than other deceased (28.3% vs.
49.2%).
Validity of NT-proBNP for predicting heart failure
We verified that NT-proBNP blood concentration could be used
instead of serum in forensic settings (Fig. 3a). Concentrations
were logged and regression was used to compare findings. In
forensic settings, 58.5% of the variance of blood values can be
explained from serum values using the following equation:
NT-proBNPserum=e
0.91·ln(NT-proBNPblood)+1.1. Therefore, the
standard serum cut-off value of >112 pg/mL of NT-proBNP
is equivalent to >220 pg/mL of NT-proBNP blood concen-
tration for our sample.
Using a standard cut-off value of >220 pg/mL of NT-
proBNPblood to define heart failure, 37/73 (50.7%) subjects
with this condition were detected positive (sensitivity),
whereas 26/95 (72.6%) individuals without heart failure
had a NT-proBNPblood≤220 pg/mL (specificity).
Area under the receiving operator curve (Fig. 2) was of
65.4%, with a confidence interval of 95% (CI 95%), from
57.1 to 73.7. An optimal diagnosis test would have an area
under the curve of 100%, whereas a test which has no
predictive diagnosis ability would have an area of 50%
Autopsies
n=210
Eligible
n=173
Excluded 37
Putrefaction 24
Younger than 15 years 13
No heart failure
n=99
Heart failure
n=74
Included in analysis
n=95
Included in analysis
n=73
Missing data
4 No available blood 1
Fig. 1 Flow chart indicating the studied population and the excluded
cases
852 Int J Legal Med (2011) 125:849–856
[18]. When including only cases for which heart failure was
either considered certain (n=27), or most unlikely (n=49)
the area under the receiving operator curve was of 67.8 (CI
95% 55.1 to 80.5). Sensitivity, specificity, predictive values
and likelihood ratios of NT-proBNP for detecting heart
failure are given with CI 95% in Table 2.
Correlation of NT-proBNP values in different body fluids
Body fluids other than blood were available for 89
autopsies. Correlation was highest between blood and
vitreous humor (R2=0.658; CI 95% 0.52 to 0.76), then
between blood and pericardial fluid (R2=0.397; CI 95%
0.21 to 0.56). R2 corresponds to the proportion of variance
explained by the correlated variable (identical to the
squared Pearson’s correlation value) and ranges from 0 to
1, where 1 is a perfect correlation. We also observed that
NT-proBNP values were most often much higher in
pericardial fluid than in other fluids (Fig. 3b, c).
Sensitivity and specificity of NT-proBNP
for sub-populations
Sensitivity and specificity of NT-proBNP across studied
sub-populations are given in Table 3. BMI and presence of
other diseases known to influence NT-proBNP levels do not
seem to influence sensitivity and specificity of the test
(Table 3). We, however, observed a lower specificity for
subjects who died from natural events, compared to those
who died from traumatic causes (23.1 vs. 82.1). There was
also a trend towards age and gender differences with higher
specificity for older men compared to lower specificity for
older women (100 vs. 16.7).
Discussion
We have investigated the ability of NT-proBNP blood
values to detect heart failure at post mortem examination by
measuring its sensitivity, specificity, positive and negative
predictive values and likelihood ratios as well.
NT-proBNP blood concentrations can corroborate the
pathological findings in cases of natural death related to
heart failure, as demonstrated by the substantial agreement
(kappa=0.61) reached among the three experts who
evaluated the autopsy reports. This is an important finding,
which shows that NT-proBNP retains its diagnostic value,
already well-established in the clinical setting [2–4, 7, 19–
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Table 2 Validity of NT-proBNP to detect heart failure at post mortem
examination
Values CI 95%
Sensitivity 50.7% 38.8% to 62.5%
Specificity 72.6% 62.4% to 81.0%
Predictive values
Positive 58.7% 45.6% to 70.8%
Negative 65.7% 55.7% to 74.5%
Likelihood ratio
Positive 1.9 1.2 to 2.8
Negative 0.68 0.53 to 0.86
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24]. Combining our observations with the results of a
previous study demonstrating the stability of this biomarker
in post mortem samples [12], we have shown—for the first
time up to now—that a biomarker keeps its diagnostic
features unaltered passing from the ante mortem to the post
mortem setting. This differentiates NT-proBNP from other
markers of cardiac pathologies, whose diagnostic validity
using post mortem material is controversial. For example,
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Fig. 3 Correlations between
NT-proBNP blood values and
those measured in other body
fluids
Sensitivity Specificity
All cases 50.7 (38.8 to 62.5) 72.6 (62.4 to 81.0)
Age/gender
Men under 55 years 39.3 (22.1 to 59.3) 85.2 (72.3 to 92.9)
Men 55 years or over 53.8 (33.7 to 72.9) 100 (46.3 to 100)
Women under 65 years 45.5 (18.1 to 75.4) 56.7 (37.7 to 74.0)
Women 65 years or over 87.5 (46.7 to 99.3) 16.7 (0.1 to 63.5)
BMI
≤30 kg/m2 51.9 (38.0 to 65.5) 73.3 (61.7 to 82.6)
>30 kg/m2 47.4 (25.2 to 70.5) 70.0 (45.7 to 87.2)
Pathologies
With other pathologiesa 58.0 (43.3 to 71.5) 65.8 (48.6 to 79.9)
Without other pathologiesa 34.8 (17.2 to 57.2) 77.2 (63.8 to 86.8)
Cause of death
Natural deaths 46.3 (31.0 to 62.4) 23.1 (6.2 to 54.0)
Violent death with trauma 59.3 (39.0 to 77.0) 82.1 (71.4 to 89.5)
Table 3 Sensitivity and
specificity of NT-proBNP to
detect heart failure for different
sub-populations
a Concerns pathologies known
to influence NT-proBNP values
(renal, pulmonary and central
nervous system pathologies)
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troponins (I and T) are known to be the preferred markers
for the laboratory diagnosis of myocardial infarction in the
clinical setting [25, 26]. Conversely, in the post mortem
context, not only they are not specific for myocardial injury,
as they increase also in other conditions [27, 28], but also
their levels are influenced by the post mortem interval [28–
30]. Some authors even pointed out that post mortem blood
is an unsuitable sample to measure cardiac troponins [31].
Our results are in accordance with clinical data regarding
the factors influencing the increase of NT-proBNP levels
[1–3, 5, 6]. Likewise, subjects who were diagnosed with
heart failure at post mortem examination were shown to be
more likely to present other diseases known to influence
NT-proBNP values, as renal, pulmonary and central
nervous system pathologies, thus still confirming the
clinical data. In fact, it is known that the levels of natriuretic
peptides may rise in some pathological situations, such as
renal pathologies, disorders associated with diastolic dys-
function, primary pulmonary hypertension, cor pulmonale,
pulmonary embolism, congenital heart diseases and
arrhythmogenic right-ventricular dysplasia [3]. This can
also explain why we observed a lower specificity of NT-
proBNP to detect heart failure for subjects who died from
natural causes compared to those who died from traumatic
events. Our finding that victims who died from traumatic
causes were two times less likely to suffer from heart failure
than other deceased (28.3% vs. 49.2%) can be related to the
short agonal period which characterised most of these
traumatic deaths.
In this study, we have also evaluated the correlations of
NT-proBNP blood values with different body fluids,
namely serum, pericardial fluid and vitreous humor. We
found out that the correlation was highest between blood
and vitreous humor (R2=0.658), and then between blood
and pericardial fluid (R2=0.397). This is in discordance
with the results of a previous study [12], which found a
weak correlation with vitreous humor. In the mentioned
study, however, values were not transformed before testing
correlations. Our log-transformed values confirm the
vitreous humor as a good substrate for post mortem
biochemical testing [32–37]. Furthermore, the ascertain-
ment that blood levels correlate well with those of vitreous
humor and pericardial fluid is important, because in
forensic practice, the latter body fluids might not be
available, like in putrefied corpses. This means that in such
cases where the autopsy investigation is obviously limited,
an increased NT-proBNP blood value may give indication
about the natural origin of death.
Beside this, we observed that NT-proBNP values were
most often much higher in pericardial fluid than in other
fluids. A possible explanation for this is that biochemical
markers reach the pericardial fluid through passive diffu-
sion and ultrafiltration due to pressure gradient, so they are
detectable in higher concentration in pericardial fluid before
they reach the other fluids [38–41].
In conclusion, our study shows that NT-proBNP has
similar diagnostic properties in the post mortem setting as it
has in the clinical one. However, a systematic dosage of this
biomarker in body fluids of fresh corpses is unjustified
because it has a low validity (with a sensitivity of 50.7%
and a specificity of 72.6%) to detect heart failure. This is
not due to an inappropriate choice of a cut-off point set at
220 pg/mL, as the area under the receiver operating curve
also shows low predictive ability (AUC=65.4%). For this
reason, it is suggested to use the standard macro- and
microscopical methods to detect heart failure at post
mortem examination, eventually validated by immunohis-
tochemical studies [42, 43]. Conversely, in putrefied
bodies, where autopsy is limited, increased NT-proBNP
blood levels can give indication about the (natural) manner
of death, in the absence of traumatic lesions during
radiological examination.
Limitations
The study does not have enough power to truly identify
clinically significant differences in sensitivity or specificity
in sub-populations. Sensitivity and specificity of the
reference test we used (autopsy findings) remain unknown.
Linearity of NT-proBNP concentrations in vitreous humor
and pericardial fluid was not tested.
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